Clinical Trial Update: Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating afatinib and cetuximab for EGFR exon 20 insertion-positive non-small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Cetuximab (cetuximab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED